Fig. 2: Symptom improvement over time for Phase I and II by CYP2C19 and CYP2D6 metabolizer group. | Translational Psychiatry

Fig. 2: Symptom improvement over time for Phase I and II by CYP2C19 and CYP2D6 metabolizer group.

From: Effects of CYP2C19 and CYP2D6 gene variants on escitalopram and aripiprazole treatment outcome and serum levels: results from the CAN-BIND 1 study

Fig. 2

During Phase I, A CYP2C19 or B CYP2D6 metabolizer groups did not have a significant influence on symptom improvement over time. During Phase II, for the ESC-Only treatment arm, the average symptom improvement from baseline for every two-week assessment trended towards being lower in C CYP2C19 IM + PMs compared to NMs, which was not observed in the ESC + ARI group. There were no associations between symptom improvement over the course of Phase II and D CYP2D6 metabolizer groups for any of the treatment arms. All linear mixed effects analyses were adjusted for age, ancestry, sex, and interaction between time and CYP2C19 and CYP2D6 metabolizer groups as fixed effects, and recruitment site and subject as random effects variables. Error bars represent standard error. ARI aripiprazole, ESC escitalopram, IM intermediate metabolizer, NM normal metabolizer, PM poor metabolizer, RM rapid metabolizer, UM ultra-rapid Metabolizer. # indicates trend with q between 0.050 and 0.070.

Back to article page